Paragon Bioservices Completes Expansion into New Facility, Adds GMP Manufacturing to its Service Catalog
BALTIMORE, MD — MAY 14, 2009 — Paragon Bioservices announced that it has completed its expansion into a new, state-of-the-art 21,000 sq ft facility at the UMB BioPark in Baltimore, Maryland. The new facility features executive offices and laboratories for research and process development services—as well as suites for cell banking and GMP manufacturing of biologics.
“Paragon is now uniquely positioned to offer a comprehensive portfolio of contract research and manufacturing services—capable of helping clients go from the research bench into process development and, ultimately, into GMP manufacturing of Phase I/II therapeutic proteins, vaccines and reagents for diagnostics,” said Marco A. Chacón, Ph.D., President and CEO of Paragon Bioservices.
Chacón added, “Paragon’s clients can now leverage our versatile infrastructure and expertise towards greater efficiency, speed to the clinic, and overall savings.”
ABOUT PARAGON BIOSERVICES
Founded in 1990, Paragon’s mission is to partner with pharmaceutical and biotechnology companies, as well as academic laboratories, in accelerating the development of biopharmaceuticals. Paragon has anticipated the research and manufacturing needs of these sectors and has worked diligently in structuring an integrated series of services in response to these needs. With 90% of its revenues coming from out-of-state, Paragon will continue to showcase Baltimore and Maryland among the leading Pharmaceutical and Biotechnology companies.
Paragon Bioservices is located at the UMB BioPark and the Johns Hopkins Bayview Research Campus, both located in Baltimore, Maryland—in general proximity to the FDA, NIH, prestigious academic institutions and the Maryland biotechnology hub.
Todd Carver – VP, Business Services and Administration
Paragon Bioservices, Inc.